NCT06682728View on ClinicalTrials.gov

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

PHASE2RecruitingINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions

Urothelial CarcinomaMuscle-invasive Bladder Cancer

Interventions

DRUG

Sacituzumab Govitecan (SG)

Given IV

DRUG

Nivolumab

Given IV

Trial Locations (1)

92868

RECRUITING

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

University of California, Irvine

OTHER